3rd Annual Gene Therapy for Neurological Disorders Europe

Navigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic

With systemic toxicity challenges plaguing the AAV field, low-dose CNS indications are an ideal target for gene therapy. The plethora of neurological indications dominating gene therapy pipelines vary from rare neurological disorders to more common diseases including Parkinson’s, epilepsy and neurodevelopmental disorders.

As programs advance globally, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the field’s definitive forum to showcase the European landscape’s progress and specific regulatory challenges. Gene therapy developers from all of the world, including Europe’s brightest minds in CNS gene therapy, will unite in Paris to share their research progress and host an industry-dedicated discussion.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

Speakers: Alexander Natz, Consultant, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Annahita Keravala, Senior Vice President, Head of Gene Therapy, CODA Biotherapeutics, Charlie Arber, Senior Research Fellow, University College London, Charlie Arber, Senior Research Fellow, University College London, David Uguen, Vice President, Regulatory Sciences, Orchard Therapeutics, Elena Gargaun, Clinical Research Director, R&D, Neurology Development, Sanofi, Fiona Marley, Head of Highly Specialised Commissioning, NHS England, José Lanciego, Staff Scientist, Functional Neuroanatomy of the Basal Ganglia Lab, University of Navarra, Laurent Desire, Director, Preclinical Development, Sensorion, Maria Beatrice Panico, Leading Senior Medical Assessor, Clinical Investigations & Trials, Science, Research & Innovation Group, Medicines & Healthcare Products Regulatory Agency, Maria Grazia Biferi, CNS Preclinical Research Lead, Spark Therapeutics, Michael Linden, Founder & Chief Scientific Officer, Handl Therapeutics; Gene Therapy Leadership, UCB, Miroslaw Zabek, Professor of Neurosurgery, Interventional Neuro Center, Neurosurgery Clinic CMKP, Mazowiecki Szpital Brodnowski, Mazowiecki Szpital Brodnowski; UniQure Huntington’s Program, Mitra Tavakkoli, Head of Neurodevelopmental Disorders & Genetic Epilepsies, Vice President, Clinical Development, Taysha Gene Therapies, Nathalie Cartier-Lacave, Research Director, INSERM; CNS, AskBio, Nicole Déglon, Professor, Département des Neurosciences Cliniques (DNC), Laboratoires des Neurothérapies Cellulaires et Moléculaires, Centre Hospitalier Universitaire Vaudois, Patrick Downey, Director, Neurodegeneration, UCB, Paulo Falabella, Vice President - Clinical Development & Operations, REGENXBIO, Richard Porter, General Manager, Epilepsy - Corlieve Subsidiary, UniQure, Rodolphe Clerval, Chief Executive Officer, COAVE THERAPEUTICS, Stéphane Palfi, Chef de Service de Neurochirurgie, Directeur Equipe de recherche, Hôpital Henri Mondor, Université Paris-Est Créteil (UPEC), Thomas Chalberg, Founder & Chief Executive Officer, Genascence Corp., Tim Goble, Senior Director, Device Development & Product Delivery, Sio Gene Therapies

Others Details

Brochure: https://go.evvnt.com/1075884-2?pid=6581